ETR:EVT Evotec (EVT) Stock Price, News & Analysis → Nvidia’s Quiet $1 Trillion Pivot (From Weiss Ratings) (Ad) Free EVT Stock Alerts €8.83 -0.16 (-1.78%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range€8.77▼€9.0950-Day Range€8.40▼€14.4752-Week Range€8.52▼€24.44Volume747,927 shsAverage Volume1.36 million shsMarket Capitalization$1.56 billionP/E RatioN/ADividend Yield2.63%Price TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get Evotec alerts: Email Address Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. About Evotec Stock (ETR:EVT)Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.Read More EVT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVT Stock News HeadlinesMay 29, 2024 | finanznachrichten.deEvotec erneut unter Druck - wichtige Unterstützung in GefahrMay 28, 2024 | finanznachrichten.deEvotec SE: Evotec and CHDI Foundation Extend Strategic Drug Discovery Collaboration in Huntington's DiseaseMay 28, 2024 | markets.businessinsider.comEQS-News: Evotec and CHDI Foundation extend strategic drug discovery collaboration in Huntington’s diseaseMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed: Evotec AG’s Anticipated Recovery and Growth PotentialMay 22, 2024 | markets.businessinsider.comEvotec AG Earns Buy Rating on Strong Biologics Growth and Strategic RealignmentsApril 22, 2024 | finance.yahoo.comSernova Welcomes Dr. Bernd Muehlenweg as Evotec's Nominee for its Board of DirectorsApril 20, 2024 | finanznachrichten.deEvotec SE: Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis TreatmentsApril 18, 2024 | markets.businessinsider.comEQS-News: Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatmentsApril 17, 2024 | finanznachrichten.deEvotec beruft Aurélie Dalbiez in den VorstandApril 17, 2024 | finanznachrichten.deEvotec SE: Evotec welcomes Aurélie Dalbiez as Chief People OfficerApril 17, 2024 | markets.businessinsider.comEQS-News: Evotec welcomes Aurélie Dalbiez as Chief People OfficerApril 17, 2024 | finance.yahoo.comEvotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024April 13, 2024 | finanznachrichten.deANALYSE: Deutsche Bank hebt Evotec auf 'Buy' - Frust nach Chef-Abgang überwundenMarch 29, 2024 | finanznachrichten.deBiotech Report: Evotec klettern, Qiagen festMarch 15, 2024 | finanznachrichten.deEvotec-Aktie: Das wird spannendMarch 6, 2024 | markets.businessinsider.comEQS-News: Evotec and Claris Ventures streamline access to accelerate programmes from Claris's portfolio companies into the clinicFebruary 22, 2024 | finanznachrichten.deEvotec Aktie sucht Boden: Kommt jetzt die große Wende nach oben?Evotec Aktie sucht Boden: Kommt jetzt die große Wende nach oben?February 6, 2024 | finanznachrichten.deEvotec: Aktie fällt und fällt - das ist jetzt wichtigFebruary 3, 2024 | finanznachrichten.deEvotec-Aktie fällt unter wichtige Marke. Wie sollen Anleger jetzt reagieren?January 22, 2024 | finance.yahoo.comEvotec SE: Invitation to Conference CallJanuary 8, 2024 | markets.businessinsider.comEQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers SquibbJanuary 8, 2024 | finance.yahoo.comEvotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers SquibbJanuary 3, 2024 | markets.businessinsider.comEQS-Adhoc: Evotec announces CEO transitionJanuary 3, 2024 | finanznachrichten.deEvotec SE: Evotec Announces CEO TransitionJanuary 3, 2024 | markets.businessinsider.comEQS-News: Evotec announces CEO transitionSee More Headlines Receive EVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolETR:EVT CUSIPN/A CIKN/A Webwww.evotec.com Phone+49-40-560810FaxN/AEmployees5,061Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)(€0.50) Trailing P/E RatioN/A Forward P/E Ratio59.96 P/E Growth0.98Net Income$-83,910,000.00 Net Margins-10.74% Pretax MarginN/A Return on Equity-7.27% Return on Assets0.03% Debt Debt-to-Equity Ratio55.91 Current Ratio1.94 Quick Ratio2.97 Sales & Book Value Annual Sales$781.43 million Price / Sales2.00 Cash Flow€2.56 per share Price / Cash Flow3.45 Book Value€6.33 per share Price / Book1.39Miscellaneous Outstanding Shares177,190,000Free FloatN/AMarket Cap$1.56 billion OptionableNot Optionable Beta1.17 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Mario Polywka DPHIL (Age 61)Ph.D., Interim CEO, Member of the Management Board & Member of the Supervisory Board Dr. Werner Lanthaler M.B.A. (Age 56)MPA, Ph.D., Member of Management Board Comp: $1.32MDr. Cord Dohrmann Ph.D. (Age 60)Chief Scientific Officer & Member of Management Board Comp: $804kDr. Craig Johnstone Ph.D. (Age 54)COO & Member of Management Board Comp: $712kDr. Matthias Evers Ph.D. (Age 51)Chief Business Officer & Member of Management Board Comp: $636kMs. Laetitia Rouxel (Age 50)CFO & Member of Management Board Ms. Anja BoslerPrincipal Accounting Officer and Senior Vice President of Group AccountingMr. Volker BraunExecutive VP and Head of Global Investor Relations & ESGDr. Christian DargelEVP Global Head of Legal & ComplianceGabriele HansenSenior VP & Head of Global Corporate Communications & MarketingMore ExecutivesKey CompetitorsSTADA Arzneimittel AktiengesellschaftETR:SAZTeva Pharmaceutical IndustriesFRA:TEVMerck KGaAETR:MRKGerresheimerETR:GXIMorphoSysETR:MORView All Competitors EVT Stock Analysis - Frequently Asked Questions How have EVT shares performed in 2024? Evotec's stock was trading at €21.28 at the beginning of 2024. Since then, EVT shares have decreased by 58.5% and is now trading at €8.83. View the best growth stocks for 2024 here. What other stocks do shareholders of Evotec own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evotec investors own include Agilent Technologies (A), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD), Anthem (ANTM), AxoGen (AXGN), Bank of America (BAC), Booz Allen Hamilton (BAH), Biohaven (BHVN), Biogen (BIIB) and Blueprint Medicines (BPMC). This page (ETR:EVT) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredWarren Buffett & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Evotec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.